The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel |
| |
| Authors: | Frank Amico Angela Amico Jennifer Mazzoni Mark Moshiyakhov William Tamparo |
| |
| Institution: | 1. Department of Cardiology, Deborah Heart Lung and Center, Browns Mills, NJ, USA;2. Department of Pharmacy, St Johns University, Queens, NY, USA;3. Department of Internal Medicine, New York Hospital Queens, Flushing Queens, NY, USA |
| |
| Abstract: | Review of: Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009; 361(11): 1045–1057. For acute coronary syndrome (ACS), a dual antiplatelet regimen comprised of treatment with aspirin and either P2Y12 adenosine diphosphate receptor antagonists, clopidogrel, prasugrel or ticagrelor is usually employed. This article compares clopidogrel with ticagrelor for the prevention of vascular events and death in broad population of ACS patients ranging from UA, NSTEMI to STEMI, utilizing planned strategies of medical or invasive treatment strategy. |
| |
| Keywords: | STEMI acute coronary syndrome ticagrelor PLATO trial |
|
|
